tada, that is very good news! Thanks.

I have really begun to realize that the amount of evidence required for suitors such as BP to jump in is very large indeed. Looks like apabetalone might have the safety component nailed but we have a long time to go. In terms of efficacy we know nothing about 3 point MACE. FA will be the first hint because as I understand it the review board will judge safety and efficacy and the efficay component is based on BOM having a "reasonable chance" of achieving the end target of 30% RRR on 3 point MACE. I really thought a couple of years ago that AZ would be chomping at the apabetalone bit. Not so. I did think all of the chemical post hoc research would entice interest.

Then regarding enzalutimide for mCRPC I am hoping zen3694 (apologies for talking about Zenith here) will be a big enhancement of the lifespan effectiveness of enzalutimide. I say this because of Don's description of the MOA of zen3694. Of course we have to see something from the trial.

However, from what I recall when Pfizer bought 50% of enzalutimide for $14 billion enzalutimude had been on the market as a SOC drug for 3 or 4 years for mCRPC i.e. many years of in market use.

My bottom line remains that RVX and Zenith have leads in the break through science of epigenetics. In particular apabetalone is leading edge because it is the only epigenetic drug involved in CVD trials.

I hope the science people keep me honest in my interpretations and I am sure they will.

I am enough of a science junkie to fully understand that innovations in science and medicine are not easily adopted by the broader scientific communities. The FDA is extremely conservative. Doctors are extremely conservative in adoption of new approaches.

That being said from my perspective Eastern, Hepalink, NGN, CV Ventures, etc understand this. The financial issue is of no concern to me. It will get done but it could screw retail shareholders like me but I doubt it. This is all about time and science. Will Eastern or others try to take this over...not without keeping the team.

GLTA

Toinv